RESUMO
<p><b>OBJECTIVE</b>To investigate the safety and feasibility of dose dense chemotherapy in the postoperative adjuvant treatment for breast cancer.</p><p><b>METHODS</b>The data of 114 breast cancer patients treated with adjuvant dose dense chemotherapy was retrospectively analyzed.</p><p><b>RESULTS</b>114 breast cancer patients received postoperative adjuvant dose dense chemotherapy from Jan. 2004 to March 2005. The patients were treated with different regimens according to their recurrence risk: 43 with paclitaxel + epirubicin (PE), 8 with taxotere + epirubicin (TE), 36 with cyclophosphamide + epirubicin + 5-Fu ( CEF) and 27 with epirubicin +5-Fu (EC). Totally, 111 patients except 3 completed the dose dense chemotherapy smoothly. Major toxicities severer than grade III included: neutropenia in 6.3% of the patients, nausea and vomit in 11.7%, peripheral neuropathy in 3.6%.</p><p><b>CONCLUSION</b>Postoperative adjuvant dose dense chemotherapy for breast cancer patient is feasible and safe, but the long-term outcome still needs further observation.</p>